Background: Recent studies have concluded that i.v. dexamethasone can prolong the duration of peripheral nerve blockade. We hypothesized that a 4 mg dose would equally prolong the duration of psoas compartment blocks (PCBs) when compared with 8 mg, and that both doses would prolong the duration when compared with placebo.
Peripheral nerve blocks (PNBs) utilizing local anaesthetic medications are a mainstay in regional anaesthesia for providing postoperative analgesia. Whilst clinicians may choose to place a perineural catheter in order to extend the duration of analgesia, this technique requires additional skills, time, and resources beyond that which are typically required for a single-injection procedure. For these reasons, a significant amount of research has been devoted to identifying ways to prolong the duration of analgesia provided by a singleinjection PNB. One area of focus has been the addition of adjuvant medications to the local anaesthetic. Medications that have been previously investigated include clonidine, buprenorphine, tramadol, midazolam, and neostigmine. 1 Recently, dexamethasone, a glucocorticoid with minimal mineralocorticoid effect, has also garnered significant interest as a potential adjuvant analgesic medication. Several studies have concluded that it may be capable of prolonging the duration of PNB when administered perineurally (off-label use) along with local anaesthetics. 2e4 These investigations followed the finding that i.v. administered dexamethasone could improve the overall quality of recovery and decrease opioid consumption in certain surgical populations. 5 Interestingly, it has since been suggested that i.v. dexamethasone may also prolong the duration of PNB when administered in doses ranging from 2.5 to 10 mg. 6e14 However, this effect has not been consistently reproducible. 15 There are several potential explanations for the inconsistent findings related to the ability of i.v. dexamethasone to prolong PNB. One is that, to date, all studies have utilized a surrogate outcome to quantify block duration rather than objectively measuring it, likely because the latter is clinically cumbersome. To complicate matters further, the surrogate end point chosen has varied amongst studies. Whilst some studies have relied on quality of recovery surveys or patient-quantified block duration, other studies have used time to first analgesic request as an indicator of block duration. Unfortunately, many of these surrogate end points actually measure the duration of analgesia rather than the duration of the nerve blockade. Whilst both the duration of analgesia and the duration of the actual nerve blockade may be clinically relevant, it is important to recognize that an intervention may affect one without affecting the other. Another potential explanation is that both perineural and i.v. routes are often studied simultaneously, making it difficult to distinguish the effect of one route from the other. For this reason, some authors have suggested that perineural and systemic dexamethasone studies should be performed independently in order to better understand the effects of each on the duration of PNB. 16 Lastly, the dose of i.v.
dexamethasone has varied between studies, and, to date, the optimal dose remains unknown. Based on the results of previous studies, which demonstrated that 8 mg of i.v. dexamethasone effectively prolongs PNB, we investigated whether a 4 mg dose would be equally effective when using an objective end point of serial pinprick sensory testing to determine block duration. 6, 13, 14 We hypothesized that both 8 and 4 mg doses of i.v. dexamethasone would prolong the duration of a psoas compartment block (PCB) to an equivalent extent, and that both doses would prolong the duration when compared with placebo.
Methods
This was a double-blind, prospective, randomised, placebocontrolled, dose-dependent, equivalency trial performed at a single centre. We received Institutional Review Board approval before the initiation of the study, and it was prospectively registered at clinicaltrials.gov (NCT02464176). Written informed consent was obtained from all patients. Patients, 18e90 yr of age, presenting to the Wake Forest Baptist Medical Center for primary elective total hip arthroplasty (THA), were eligible. Patients were excluded if they had contraindications to regional anaesthesia (allergy to amide local anaesthetics, coagulopathy, or infection in the area of the anticipated PCB), peripheral neurological dysfunction or neuropathy, insulin-and non-insulin-dependent diabetes mellitus, systemic corticosteroid use within 30 days of surgery, chronic opioid use (!40 mg of oxycodone equivalents daily or any long-acting opioid), pregnancy, allergy or adverse reaction to dexamethasone (i.e. psychosis), or the inability to comprehend or reliably participate in the study.
The study was conducted from May 2015 to November 2016, and 115 participants were randomized into three groups. All patients received a PCB with 25 ml of bupivacaine (2.5 mg ml À1 ) with 1:200 000 epinephrine. After block placement, Group 1 received i.v. normal saline (placebo¼dexamethasone 0 mg), Group 2 received i.v. dexamethasone 4 mg, and Group 3 received i.v. dexamethasone 8 mg. Block randomisation of patients occurred through the use of sequentially numbered opaque sealed envelopes where both the patient and the study investigators were blinded to the randomisation. All i.v. study medications were prepared by a physician anaesthesiologist not involved in patient assessment, and given in equal volumes (2 ml) in syringes marked 'study drug' to preserve blinding. Unless contraindicated, each patient received the following oral premedication for analgesia: paracetamol 1 g, celecoxib 400 mg, and pregabalin 150 mg. Monitoring throughout the PCB procedure consisted of pulse oximetry, electrocardiogram, non-invasive blood pressure, and end-tidal carbon dioxide. After i.v. sedation with midazolam and fentanyl as needed, a nerve-stimulator-guided PCB was performed, as described by Capdevila and colleagues. 17 The primary outcome was duration of sensory blockade in the distribution of the lumbar plexus as determined by the pinprick sensation. Secondary outcomes included rest and movement pain scores [numeric rating scale (NRS) 0e10] at time 0 (baseline pain determined before operation in the holding room), 6, 12, 18, 24, and 30 h after block placement. The time to first analgesic request and total opioid consumption in oxycodone equivalents over 30 h were also assessed. 18 
Power analysis
The primary sample-size consideration was a comparison between the 4 and 8 mg dexamethasone groups, where the goal was to demonstrate that PCB duration was clinically equivalent between the two groups. Note that this hypothesis, statistically, is reversed from what is usually tested in a superiority, or inequality, trial. The margin (delta) for equivalence when comparing the PCB duration between the 4 and 8 mg groups was set at (À4, 4) or within a four hour difference between groups. A previously published study reported a mean supraclavicular PNB duration of 25.2 h [95% confidence interval (CI): 17.6e23.6] using patient-determined duration of analgesia after i.v. dexamethasone 8 mg. 6 This study, which relied on a surrogate outcome for block duration, was used for our power analysis, as no prior study has used objective serial neurological testing to determine if dexamethasone prolongs PNB. In order to permit power calculations, an assumption about the true difference in mean duration was required. We assumed that the true mean duration for dexamethasone 4 mg was ±1.5 h from the true mean duration for 8 mg. With a standard deviation (SD) of 3.95 used for the sample-size calculation, a study of 50 participants per group (allowing for 10% dropout) would have >80% power to declare the two doses clinically equivalent. We recruited a reduced sample size for the placebo control group, as the difference in the duration of PCB when compared with both dexamethasone groups was expected to be large. Provided the average duration of PCB was at least 5 h longer for either dexamethasone group, we calculated >90% power, with a two-sided a of 0.05 and an SD of 3.95, recruiting only 15 patients (allowing for 10% dropout) to the placebo control group. A previous study reported an average increase of 11.8 h when comparing i.v. dexamethasone 8 mg to their placebo control group. 6 
Statistical analysis
To test for the equivalence between the 4 and 8 mg doses in terms of time to sensory recovery after nerve blockade, the two one-sided test (TOST) procedure was used. 19 Testing for a difference of 4 h, the two doses were considered to be equivalent if the 90% CI for the differences was contained within (e4, 4). To assess further the differences in block-duration times, total opioid consumption, and pain scores, a one-way analysis of variance (ANOVA) was used with post hoc multiple comparison tests (MCTs) performed using TukeyeKramer. To test for the time to first analgesic differences, a proportional hazards regression model was created to compare the three groups. The KaplaneMeier method was also used to estimate the median. 20 Categorical data were analysed utilizing Fisher's exact test. All outcomes were compared using a conventional a level of 0.05. SAS version 9.4 (Cary, NC, USA) was used in all statistical analyses. Given the equivalency design of this study, the primary analysis of the data is based on an intention-to-treat analysis (ITA). A per-protocol analysis (PPA) was also performed.
Results
Intention-to-treat analysis Subject characteristic data and the perioperative medication administration for the three groups can be found in Table 1 . There were no differences between the groups in regards to the postoperative administration of paracetamol (P¼0.35), celecoxib (P¼0.57), or pregabalin (P¼0.83). There was no statistical difference (P¼0.35) in patients receiving spinal vs general anaesthesia with all 15 subjects in the placebo group, 46 of 50 in the 4 mg group, and 49 of the 50 subjects in the 8 mg group receiving a spinal anaesthetic. Of note, whilst two subjects declined spinal placement (both in the 4 mg group), the remaining subjects that received general anaesthesia did so as a result of a failed spinal (three patients in total). For the three subjects that experienced a protocol violation, all data related to the primary outcome were available. For the three subjects with a failed block and the single subject with an aborted block, a PNB duration of 0 h was assumed, as this was felt to be the most conservative approach. The same assumption was made for the one patient whose surgery was cancelled, as serial block assessments could not be performed given discharge from the hospital.
The PCB durations for the placebo group, the dexamethasone 4 mg group, and the dexamethasone 8 mg group were [mean (SD)] 19.6 h (6.7), 18.5 h (8), and 18.1 h (7.1), respectively ( Table 2 ). The resulting TOST procedure found a mean difference of 0.4 with a 90% CI of (e2.1e2.9 h). As the CI was completely contained within the original assumption of (e4, 4), the two block durations were deemed equivalent. The oneway ANOVA also found no difference in block duration when comparing the three groups [F (2, 112)¼0.24, P¼0.79], and this was further supported by the subsequent post hoc MCT results:
The secondary outcomes are shown in Tables 3 and 4 . For total opioid consumption at 30 h and time to first analgesic, data from all 115 patients were included in the ITA. Whilst preoperative baseline pain scores, both at rest and with movement, were available for all patients, there were a few missing postoperative pain scores. One patient in the 4 mg group did not have pain scores available for the 18 h assessment. In addition, all postoperative pain scores were unavailable for three additional subjects in the 4 mg group (one with a cancelled surgery who was lost to follow-up, and two with a failed/aborted block) and two subjects in the 8 mg group whose blocks were either aborted or failed. These data points were omitted from the ITA, and the median and inter-quartile ranges for postoperative pain scores were calculated using only the data that were available.
For the secondary outcomes of the time to first analgesic and total opioid consumption, data from all 115 subjects were included in the analysis. For the single subject whose surgery was not actually performed, the time to first opioid was censored at time zero and total opioid consumption was given a value of zero. Of note, four additional subjects in the 4 mg group and three subjects in the 8 mg group received no opioids after operation through 30 h, and were handled in a similar fashion. With these assumptions, the time to first analgesic request was not different between the 4 and 8 mg groups {hazard ratio (HR)¼1.28 [95% CI of (0.85, 1.92)]; P¼0.24}, or the placebo and the 4 mg group {HR¼1.42, [95% CI of (0.79, 2.56)]; P¼0.24}. However, the 8 mg group had a longer time to first analgesic when compared with the placebo {HR¼1.81, [95% CI of (1.01, 3.28)]; P¼0.047}. This is also illustrated in a KaplaneMeier curve (Fig 2) . In regards to total opioid consumption through 30 h after PNB, ANOVA testing revealed no differences between groups [F (2, 112)¼1.51, P¼0.23]. The post hoc MCT analysis further found no difference between the 4 and 8 mg groups (P¼0.29), the placebo and the 4 mg groups (P¼0.96), or the placebo vs the 8 mg group (P¼0.39). The NRS pain scores at all time periods, both at rest and with movement, were not different between groups (Table 4) . For more detailed comparison information, please refer to Appendix 1.
Per-protocol analysis
Of the 115 subjects originally enrolled and included in the ITA, three subjects had a protocol violation, three subjects had a failed PNB, one subject had an aborted PNB, and one subject's surgery was not performed. The distribution of these patients amongst groups can be seen in Fig 1. A PPA was performed on the 107 remaining subjects that completed treatment. Similar to the ITA, there were no statistical differences between groups for the postoperative administration of paracetamol (P¼0.78), celecoxib (P¼0.63), or pregabalin (P¼0.50). Additionally, the lack of statistical difference remained in the PPA for the number of subjects undergoing planned spinal anaesthesia vs general anaesthesia (P¼0.71). All 14 subjects in the placebo group .2), and 19.6 h (7.0) for the placebo, 4 mg group, and 8 mg group, respectively. The TOST procedure found a mean difference between the 4 and 8 mg groups of 0.6 h with a 90% CI of (e1.6e2.8 h), meaning these two groups were equivalent. Comparisons between the three groups using an ANOVA again found no difference between the groups. The post hoc MCT analysis using TukeyeKramer also found no significant For the time to first analgesic, the PPA found no difference between the 4 and 8 mg groups (P¼0.25), and the placebo vs the 4 mg group (P¼0.27). In contrast to the ITA, it also found that the placebo vs the 8 mg group comparison was not significantly different (P¼0.058). In regards to total opioid consumption at 30 h after PNB, ANOVA testing found no significant difference between the groups. The post hoc MCT testing further confirmed this: [4 vs 8 mg (P¼0.15), placebo vs 4 mg (P¼0.99), and placebo vs 8 mg (P¼0.35)]. In regards to NRS pain scores, the PPA corroborated the ITA, as no difference was found between the groups at any time point.
Discussion
The results of this study are both clinically important and surprising. Our initial hypothesis was that a dose of i.v. dexamethasone 4 mg would be equally effective as an 8 mg dose for prolonging a PCB. The results of equivalency testing allowed us to accept this initial hypothesis. We also assumed that both doses of i.v. dexamethasone would provide a prolonged duration of nerve blockade when compared with the placebo. We ultimately found that neither dose (4 or 8 mg) resulted in a PCB duration that was significantly different from the placebo. In fact, all three of the intervention groups had a mean duration of PCB that was within 1.5 h of each other with nearly identical SDs. These findings are in direct contrast to the results of multiple prior studies, which have suggested that i.v. dexamethasone prolongs PNB. Whilst some of these studies have used a dose as low as 1.25 mg, most studies have used 8e10 mg doses.
6e14 Although the exact mechanism of action has not been determined, the results of these prior studies have been perceived as being so compelling that subsequent investigations have occasionally chosen to omit a placebo group altogether. 7,9,12 Aliste and colleagues 7 went as far as to say that they 'decided to forego enrolment of a purely placebo group (IV and [perineural] normal saline) [as they] reasoned that, although the optimal method of administration remains controversial, the literature is replete with trials demonstrating that patients receiving dexamethasone fare better than those who do not in terms of onset time, block duration, postoperative analgesia, or opioid consumption'. The results of our study suggest that the conclusion that the administration of i.v. dexamethasone results in the prolongation of PNB may be challenged. In fact, at least two other studies have also failed to find a longer duration of PNB, although in these investigations lower doses of i.v. dexamethasone (1.25e4 mg) were administered. 11, 15 There are several potential reasons why our results contradict previous findings. First, most prior studies have relied on surrogate end points to determine PNB duration, such as patient-determined block resolution, time to first analgesic request, and quality of recovery surveys, rather than using an objective end point, such as serial dermatomal sensory testing. Whilst it is true that these surrogate end points might be more clinically relevant, and were therefore included as secondary end points in this study, they do not specifically answer the question of whether i.v. dexamethasone prolongs PNB duration. This study suggests that i.v. dexamethasone might have clinically relevant analgesic effects in terms of prolonging the time to first analgesic request, but this may be more related to its analgesic and euphoric effects rather than a specific ability to prolong nerve blockade. It should be noted that the reliance on a surrogate end point is listed as a limitation or weakness in many of these aforementioned studies, and some authors have even stated that, using a more objective end point, such as the one used in this study, was impossible given clinical constraints. 8e11, 14 Although performing serial examinations to determine block duration is time consuming, we specifically chose a surgical procedure that allowed for consistent overnight hospital admission so that subjects could be reliably evaluated every 2 h.
Secondly, there appears to be a doseeresponse relationship for the analgesic effect of i.v. dexamethasone. Whilst studies using lower doses of i.v. dexamethasone (1.25e4 mg) have failed to find a prolongation in the time to first analgesic request, studies using doses that approach >0.1 mg kg À1 have shown that i.v. dexamethasone provides analgesia, decreases opioid consumption, and improves quality of recovery. 2, 11, 15 If these outcomes are used as surrogates for PNB duration, it is likely that it was incorrectly concluded that block duration was prolonged. The ITA portion of our study further supports that higher doses of i.v. dexamethasone may improve analgesia, as only the dose of i.v. dexamethasone 8 mg resulted in a prolonged time to first analgesic when compared with the placebo. Despite the delayed time to first analgesic request in the 8 mg group, we found that pain scores, both with rest and movement, were not statistically different between any group comparisons at any post-block time point in both the ITA and PPA. Unlike other investigations, we were not able to find a difference in opioid consumption between any of the groups in either the ITA or PPA, although this study was not specifically powered for this outcome.
Our statistical analysis in this paper warrants discussion, as both an ITA and a PPA were conducted in this study. The rationale for this is that some authorities have recommended that both forms of analysis be conducted when performing an equivalency, or non-inferiority trial given concerns for bias when only one method is utilized. 21 The fact that both approaches to data analysis resulted in the same findings for the primary outcome strengthens the results of the study and our conclusions. However, it must be noted that, whilst most of our other secondary outcomes (postoperative pain scores and opioid consumption) were the same in both the ITA and PPA, the statistically significant prolongation between the 8 mg and placebo groups for the time to first analgesic request in the ITA (P¼0.047) was not observed when the PPA was used (P¼0.058). One possible explanation for this difference is that the PPA utilized fewer patients (107 instead of 115), meaning there was decreased power in the PPA. Therefore, this could have led to an increased risk of a type II error, as the PPA was no longer powered to detect a difference between groups. The only missing data points were for the secondary outcome of the NRS pain scores. We chose to account for these by omitting them from the analysis. Whilst we could have carried forward previous pain scores, this would have meant that, for all but one patient, pre-operation, collected baseline pain scores would have been used to estimate all postoperative pain levels. For this reason, we felt that omitting these data points was the most appropriate approach.
Our study has several considerations and limitations that warrant discussion. First, we did not use patient-controlled analgesia (PCA) devices, which some may argue could have allowed for a more accurate assessment of opioid consumption. The rationale behind this decision was that PCA use is not routine at our institution for patients undergoing THA. Second, the decision to exclude patients who received a steroid in the last 30 days might raise a criticism that a longer washout period may have been appropriate. However, this duration of time should have allowed for a washout of more than five halflives for all commonly used corticosteroid medications. 22 Another potential criticism of the study design is that not all patients received the same preoperative multimodal analgesics, which could have conceivably affected the postoperative pain scores or the time to first opioid consumption. We followed our usual protocol for the administration of these medications, as all patients received celecoxib, pregabalin, and acetaminophen, unless a contraindication existed. It should be noted that fewer subjects in the placebo group received pregabalin and celecoxib before operation, which could have affected our secondary-outcome comparisons. Additionally, we chose not to follow the rates of PONV, as we felt that the literature is replete with evidence that i.v. dexamethasone decreases the rate of PONV, and we felt this outcome did not warrant further proof of effect. Finally, and possibly most importantly, we had a limited number of subjects in the placebo group of the study. Our initial power analysis was based on the results of prior studies, which found a significant prolongation of PNB when i.v. dexamethasone was used. We, too, expected to find the same significant prolongation and, therefore, included a reduced number of subjects in the placebo group. We suggest that future studies involving dexamethasone continue to have a placebo group and that including an equal number of subjects in this group would be optimal.
It must be noted that our study examined a PCB and it is not clear if the findings of this study can be generalized to all other types of PNBs. However, these findings do suggest that it is critical that future studies include an objective end point for determining block duration when investigating the ability of i.v. dexamethasone to prolong PNB. The same is true for investigations involving the perineural administration of dexamethasone, as systemic absorption from the perineural route may explain why some studies using subjective surrogate end points for block duration have concluded that perineural dexamethasone prolongs PNB.
In conclusion, our study shows that, whilst a dose of i.v. dexamethasone 8 mg may delay the time to first analgesic request, which is an important clinical outcome, neither a 4 nor an 8 mg dose impacts the actual duration of sensory blockade measured by return of pinprick sensation after a PCB. The results of this study suggest that, whilst systemic dexamethasone may be useful in a multi-modal analgesic regimen, it should not be expected to prolong peripheral nerve blockade. 
